Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$3.00
-2.8%
$1.92
$0.91
$6.05
$250.71M2.153.08 million shs1.76 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$6.30
+2.2%
$6.08
$5.41
$23.48
$546.69M0.41.40 million shs1.14 million shs
Prothena Corporation plc stock logo
PRTA
Prothena
$6.58
-0.1%
$6.21
$4.32
$25.42
$353.93M0.011.08 million shs465,269 shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$10.10
-1.1%
$9.84
$6.42
$29.60
$534.30M1.07288,349 shs254,807 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+7.69%+20.31%+59.59%+177.48%-37.27%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+6.02%+6.02%-8.47%+9.41%-70.10%
Prothena Corporation plc stock logo
PRTA
Prothena
+0.92%+4.11%+25.33%-32.09%-68.07%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+3.03%+1.59%-0.49%+35.23%-43.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
4.0586 of 5 stars
3.23.00.04.31.12.50.6
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4.5511 of 5 stars
4.43.00.04.71.90.80.6
Prothena Corporation plc stock logo
PRTA
Prothena
3.0556 of 5 stars
4.22.00.00.01.01.71.3
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
1.7697 of 5 stars
3.50.00.00.01.63.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.31
Hold$4.7056.93% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$24.50289.14% Upside
Prothena Corporation plc stock logo
PRTA
Prothena
2.33
Hold$31.50379.01% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
3.00
Buy$30.83205.43% Upside

Current Analyst Ratings Breakdown

Latest EDIT, PRTA, KURA, and TYRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/26/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/20/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$36.00
6/20/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/4/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
5/28/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underperform
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$6.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$32.31M7.76N/AN/A$1.63 per share1.84
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$53.88M10.12N/AN/A$5.32 per share1.18
Prothena Corporation plc stock logo
PRTA
Prothena
$135.16M2.62N/AN/A$9.05 per share0.73
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$6.78 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)
Prothena Corporation plc stock logo
PRTA
Prothena
-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$86.48M-$1.63N/AN/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)

Latest EDIT, PRTA, KURA, and TYRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.40N/AN/AN/A$1.81 millionN/A
8/6/2025Q2 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.53N/AN/AN/AN/AN/A
5/12/2025Q1 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million
5/8/2025Q1 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million
5/8/2025Q1 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.49-$0.47+$0.02-$0.47N/AN/A
5/1/2025Q1 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.08
3.08
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
8.07
8.07
Prothena Corporation plc stock logo
PRTA
Prothena
N/A
9.00
9.00
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
22.78
22.78

Institutional Ownership

CompanyInstitutional Ownership
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Prothena Corporation plc stock logo
PRTA
Prothena
97.08%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%

Insider Ownership

CompanyInsider Ownership
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6.40%
Prothena Corporation plc stock logo
PRTA
Prothena
9.20%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
15.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23083.71 million81.96 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.57 million81.03 millionOptionable
Prothena Corporation plc stock logo
PRTA
Prothena
13053.83 million48.88 millionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2053.09 million45.02 millionOptionable

Recent News About These Companies

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$3.00 -0.09 (-2.76%)
As of 02:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$6.30 +0.14 (+2.21%)
As of 02:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Prothena stock logo

Prothena NASDAQ:PRTA

$6.58 0.00 (-0.06%)
As of 02:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$10.10 -0.12 (-1.13%)
As of 02:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.